The AACR has released it's 2013 Cancer Progress report. The report is a comprehensive educational tool that illustrates the return on investments in cancer research and biomedical science. It discusses the various ways medical teams continue [...]
With the advent of Imatinib, tremendous progress has been made in the treatment of patients with GIST.
Dr. Brian Rubin I’ve been working on a cure for GIST most of my professional life and the initial work was both exciting and fulfilling. I remember when we confirmed the presence [...]
Members of the Life Raft Group Research Team continue to publish results of promising studies aimed at finding a cure for GIST. The latest reflects the collaboration that guides its efforts.
A study about the DREAM complex was published in the June issue of Cancer Research by LRG Research Team members Drs. Anette Duensing and Maria Debiec-Rychter.
During the past dozen years gastrointestinal stromal tumors have emerged from oncologic obscurity and reached center-stage in the development of targeted therapies for solid tumors. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effective in suppressing the growth of metastatic GIST, allowing patients to live far longer than during the previous era of ineffective chemotherapy.
Breaking Research Barriers! The Life Raft Group Research Team is unique. As we know, the purpose of research is to inform, educate and allow us to live better lives.
A Cure is Within Our Grasp! It is amazing what happens when you change what doesn't work - Our Life Raft Group Research Team is a great example of this
MSKCC is launching a clinical trial that uses a MEK inhibitor to target ETV1 in combination with imatinib on a small group of newly diagnosed GIST patients
Adrian Mariño-Enriquez explains the significance of a recently published study that will have a big impact on GIST research. Keep reading to learn the critical role of CDC37 in GIST tumors.
